BLCO Bausch + Lomb Corporation

Bausch + Lomb Corporation operates as an eye health company in Canada and internationally. It operates through three segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that cover the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions. It offers intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.

Date	Price Target	Rating	Analyst
5/2/2025	$20.00 → $15.00	Buy	H.C. Wainwright
3/28/2025	$24.00 → $15.00	Overweight → Equal Weight	Wells Fargo
12/11/2024	$24.00 → $22.00	Buy → Neutral	Citigroup
12/2/2024	$19.00	Overweight → Equal-Weight	Morgan Stanley
10/15/2024	$19.00 → $25.00	In-line → Outperform	Evercore ISI
7/10/2024	$19.00	Outperform	Raymond James
5/6/2024	$16.00 → $18.00	Equal-Weight → Overweight	Morgan Stanley
1/4/2024	$19.00 → $17.00	Outperform → In-line	Evercore ISI
12/12/2023	$16.00	Hold	Stifel
10/3/2023	$20.00	Outperform	Evercore ISI

Bausch + Lomb Corporation

Recent Analyst Ratings for Bausch + Lomb Corporation

Bausch + Lomb Corporation SEC Filings

Bausch + Lomb Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

Bausch + Lomb Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

SEC Form SD filed by Bausch + Lomb Corporation

SEC Form 8-K filed by Bausch + Lomb Corporation

SEC Form DEFA14A filed by Bausch + Lomb Corporation

Bausch + Lomb Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

SEC Form 10-Q filed by Bausch + Lomb Corporation

Bausch + Lomb Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form DEF 14A filed by Bausch + Lomb Corporation

SEC Form 10-K filed by Bausch + Lomb Corporation

Bausch + Lomb Corporation Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

CEO and Chairman of the Board Saunders Brent L bought $248,072 worth of shares (22,000 units at $11.28) and was granted 22,000 shares, increasing direct ownership by 6% to 741,156 units (SEC Form 4)

Director Von Eschenbach Andrew C. bought $19,925 worth of shares (1,695 units at $11.76), increasing direct ownership by 4% to 41,748 units (SEC Form 4)

CEO and Chairman of the Board Saunders Brent L bought $505,067 worth of shares (32,250 units at $15.66) and was granted 32,250 shares, increasing direct ownership by 11% to 627,419 units (SEC Form 4)